Risk adjustment model for tuberculosis compared to non-tuberculosis mycobacterium or latent tuberculosis infection: Center for Personalized Precision Medicine of Tuberculosis (cPMTb) cohort database
Rattachement africain : kr, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: The Center for Personalized Precision Medicine of Tuberculosis (cPMTb) was constructed to develop personalized pharmacotherapeutic systems for tuberculosis (TB). This study aimed to introduce the cPMTb cohort and compare the distinct characteristics of patients with TB, non-tuberculosis mycobacterium (NTM) infection, or latent TB infection (LTBI). We also determined the prevalence and specific traits of polymorphisms in N-acetyltransferase-2 (NAT2) and solute carrier organic anion transporter family member 1B1 (SLCO1B1) phenotypes using this prospective multinational cohort. METHODS: Until August 2021, 964, 167, and 95 patients with TB, NTM infection, and LTBI, respectively, were included. Clinical, laboratory, and radiographic data were collected. NAT2 and SLCO1B1 phenotypes were classified by genomic DNA analysis. RESULTS: Patients with TB were older, had lower body mass index (BMI), higher diabetes rate, and higher male proportion than patients with LTBI. Patients with NTM infection were older, had lower BMI, lower diabetes rate, higher previous TB history, and higher female proportion than patients with TB. Patients with TB had the lowest albumin levels, and the prevalence of the rapid, intermediate, and slow/ultra-slow acetylator phenotypes were 39.2%, 48.1%, and 12.7%, respectively. The prevalence of rapid, intermediate, and slow/ultra-slow acetylator phenotypes were 42.0%, 44.6%, and 13.3% for NTM infection, and 42.5%, 48.3%, and 9.1% for LTBI, respectively, which did not differ significantly from TB. The prevalence of the normal, intermediate, and lower transporter SLCO1B1 phenotypes in TB, NTM, and LTBI did not differ significantly; 74.9%, 22.7%, and 2.4% in TB; 72.0%, 26.1%, and 1.9% in NTM; and 80.7%, 19.3%, and 0% in LTBI, respectively. CONCLUSIONS: Understanding disease characteristics and identifying pharmacokinetic traits are fundamental steps in optimizing treatment. Further longitudinal data are required for personalized precision medicine. TRIAL REGISTRATION: This study registered ClinicalTrials.gov NO. NCT05280886.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Risk adjustment model for tuberculosis compared to non-tuberculosis mycobacterium or latent tuberculosis infection: Center for Personalized Precision Medicine of Tuberculosis (cPMTb) cohort database
- Date Crossref
- 24/11/2023
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Inje University Ilsan Paik Hospital pays non établi dans la noticeÉtablissement de santé
-
Inje University Sanggye Paik Hospital pays non établi dans la noticeÉtablissement de santé
-
Kosin University Gospel Hospital pays non établi dans la noticeÉtablissement de santé
-
Yeungnam University Medical Center pays non établi dans la noticeÉtablissement de santé
-
Korea University Department of Internal Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Korea University Guro Hospital pays non établi dans la noticeÉtablissement de santé
-
The Catholic University of Korea Incheon St. Mary's Hospital pays non établi dans la noticeÉtablissement de santé
-
Catholic University of Korea pays non établi dans la noticeUniversité ou école supérieure
-
St. Mary's Hospital pays non établi dans la noticeÉtablissement de santé
-
The Catholic University of Korea Seoul St. Mary's Hospital pays non établi dans la noticeÉtablissement de santé
-
Inje University Department of Internal Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Inje University Busan Paik Hospital pays non établi dans la noticeÉtablissement de santé
Inje University Ilsan Paik Hospital, Inje University Sanggye Paik Hospital et Kosin University Gospel Hospital, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.